🌍·23h agodiscovery
Controversial drug at center of multibillion-dollar Amgen deal faces more questions after paper retracted
Publisher
T
The Business Journals
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- The Business Journals
- Region
- Global
- Scope
- discovery
- Published
- July 2, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: The Business Journals
Scope: discovery
Related coverage
More related coverage
citybiz/3h ago
VERAXA Biotech Collaborates with ATUM on Cell Line Development to Advance Lead BiTAC®-TCE Program
Investing News Network/3h ago
Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026
UK Department of Health and Social Care/3h ago
NHS injury costs recovery scheme: April 2026 to March 2027
Data on the funds collected by the Compensation Recovery Unit and funds paid to the NHS.
Medical Daily/4h ago